Eosinophilic-Associated Diseases (EADs) extend beyond the gut, linking other inflammatory T2 conditions like EoE, asthma, and atopic dermatitis. Learn about evolving research, diagnosis challenges, and targeted biologic treatments that are transforming patient care. Read more
Discover the study findings comparing benralizumab (ABRA) and prednisolone in treating eosinophilic exacerbations of asthma and COPD. Read more
Learn how NICE and SMC policies affect your access to multi-indication drugs like Dupixent® (dupilumab) for EoE in the UK despite its availability worldwide. Discover how EOS Network's advocacy works to influence change for better access. Read more
Fasenra is now EU-approved for EGPA, offering new hope for patients with relapsing symptoms and high disease burden. Read more
Dupixent (dupilumab) becomes the first approved treatment for eosinophilic oesophagitis (EoE) in children aged 1-11 across the EU. Learn more about the study results. Read more
Fasenra (Benralizumab) gains approval in China for treating severe eosinophilic asthma, offering new hope to millions of patients with limited treatment options. Learn more about this significant advancement Read more
Messina Phase 3 trial results show benralizumab reduces eosinophil counts in EoE patients, with no notable improvement in dysphagia symptoms. Read more
Explore a study that aims to understand why some people on eosinophil-directed treatments continue to have Eosinophilic Asthma flare-ups. Read more
Discover how Fasenra outperforms Nucala in treating Granulomatosis with Polyangiitis (EGPA), offering hope for reduced steroid use and improved remission. Read more
FDA has approved Dupixent (dupilumab) for children aged one to eleven, an important step for EoE management in young children and families. Read more
Learn more about Dupixent and what impact its approval could have on treating EoE in younger children. Read more
Recent research shows weekly dupilumab outperforms bi-weekly treatments in managing Eosinophilic Oesophagitis (EoE) symptoms. Read more
Learn more about treatments that are going through investigations and trials for treating EoE. Answers CEGIR. Read more
Learn how groundbreaking research on Thymic Stromal Lymphopoietin (TSLP) offers hope for more effective and less invasive diagnoses and treatments for eosinophilic diseases like EoE. Read more
The latest USA guidance on the use of dupilumab in EoE. Insights into when and how to consider dupilumab as a first-line or step-up therapy, shared decision-making approach and monitoring outcomes. Read more
Dupilumab has been recommended for EU approval by the CHMP for the treatment of eosinophilic oesophagitis (EoE). It is the first biologic drug in the EU indicated for EoE for sufferers aged 12+. Read more
The third part of a trial investigating dupilumab in EoE has found the drug maintains its clinical, symptomatic and histologic efficacy and safety profile up to Week 52 in adults and children over 12+. Read more
October 2022 - MESSINA trial of Fasenra in EoE patients demonstrated a significant improvement in histological disease remission but not an improvement in dysphagia symptoms. Read more
The first UK patient has been recruited for the global MESSINA study for benralizumab for EoE. Find study details and see if you're eligible to take part in the Phase 3 trial. Read more
Mar 2021 - Phase 3 trial shows Dupilumab to improve health-related quality of life and reduces symptom burden in patients with EoE. Read more
Dec 2020 - AstraZeneca has begun its Phase 3 trial evaluating Fasenra in EoE and other eosinophilic diseases. It has also announced a further Phase 3 trial evaluating the drug for EG and EGE. Read more